These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
259 related items for PubMed ID: 25664254
1. Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy. Suzuki H, Kikuta T, Inoue T, Hamada U. World J Nephrol; 2015 Feb 06; 4(1):118-26. PubMed ID: 25664254 [Abstract] [Full Text] [Related]
2. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Jacobsen P, Rossing K, Parving HH. Curr Opin Nephrol Hypertens; 2004 May 06; 13(3):319-24. PubMed ID: 15073491 [Abstract] [Full Text] [Related]
3. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, Zhao N, Liu L, Lv J, Zhang H, Wang H. Am J Kidney Dis; 2016 May 06; 67(5):728-41. PubMed ID: 26597926 [Abstract] [Full Text] [Related]
4. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease. Sharma P, Blackburn RC, Parke CL, McCullough K, Marks A, Black C. Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007751. PubMed ID: 21975774 [Abstract] [Full Text] [Related]
5. Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study. Fu EL, Clase CM, Evans M, Lindholm B, Rotmans JI, Dekker FW, van Diepen M, Carrero JJ. Am J Kidney Dis; 2021 May 05; 77(5):719-729.e1. PubMed ID: 33246024 [Abstract] [Full Text] [Related]
6. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment? Caravaca-Fontán F, Valladares J, Díaz-Campillejo R, Barroso S, Luna E, Caravaca F. Nefrologia (Engl Ed); 2020 May 05; 40(1):38-45. PubMed ID: 31196659 [Abstract] [Full Text] [Related]
7. Benefits of SGLT2 inhibitors combining with renin-angiotensin-system blockers on cardiovascular outcomes in chronic kidney disease patients: A systemic review and meta-analysis. Liu T, Li R, Wang X, Gao X, Zhang X. Med Clin (Barc); 2022 Jul 22; 159(2):65-72. PubMed ID: 34872768 [Abstract] [Full Text] [Related]
8. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease. St Peter WL, Odum LE, Whaley-Connell AT. Pharmacotherapy; 2013 May 22; 33(5):496-514. PubMed ID: 23576066 [Abstract] [Full Text] [Related]
9. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Ferrari P. Nephrology (Carlton); 2007 Feb 22; 12(1):81-9. PubMed ID: 17295666 [Abstract] [Full Text] [Related]
10. The renin-angiotensin system and diabetic nephropathy. Gurley SB, Coffman TM. Semin Nephrol; 2007 Mar 22; 27(2):144-52. PubMed ID: 17418683 [Abstract] [Full Text] [Related]
11. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Balamuthusamy S, Srinivasan L, Verma M, Adigopula S, Jalandhara N, Hathiwala S, Smith E. Am Heart J; 2008 May 22; 155(5):791-805. PubMed ID: 18440325 [Abstract] [Full Text] [Related]
12. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation? Sarafidis PA, Ruilope LM. Kidney Int; 2014 Mar 22; 85(3):536-46. PubMed ID: 24048382 [Abstract] [Full Text] [Related]
13. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Siragy HM, Carey RM. Am J Nephrol; 2010 Mar 22; 31(6):541-50. PubMed ID: 20484892 [Abstract] [Full Text] [Related]
14. Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report. Weir MR, Lakkis JI, Jaar B, Rocco MV, Choi MJ, Kramer HJ, Ku E. Am J Kidney Dis; 2018 Dec 22; 72(6):873-884. PubMed ID: 30201547 [Abstract] [Full Text] [Related]
15. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Wolf G, Ritz E. Kidney Int; 2005 Mar 22; 67(3):799-812. PubMed ID: 15698420 [Abstract] [Full Text] [Related]
16. [Classical nephroprotection: Renin angiotensin aldosterone system inhibitors]. Egocheaga MI, Drak Y, Otero V. Semergen; 2023 Jun 22; 49 Suppl 1():102018. PubMed ID: 37355297 [Abstract] [Full Text] [Related]
17. Sodium-glucose cotransporter-2 inhibitors and non-steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin-angiotensin system blockade. Shenoy SV, Nagaraju SP, Bhojaraja MV, Prabhu RA, Rangaswamy D, Rao IR. Nephrology (Carlton); 2021 Nov 22; 26(11):858-871. PubMed ID: 34176194 [Abstract] [Full Text] [Related]
18. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus. Wish JB, Pergola P. Mayo Clin Proc Innov Qual Outcomes; 2022 Dec 22; 6(6):536-551. PubMed ID: 36277502 [Abstract] [Full Text] [Related]
19. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials. Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, Jia J, Yan T, Liu Y, Lin S. Drugs; 2020 Jun 22; 80(8):797-811. PubMed ID: 32333236 [Abstract] [Full Text] [Related]
20. The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease. Leon SJ, Tangri N. Can J Cardiol; 2019 Sep 22; 35(9):1220-1227. PubMed ID: 31472818 [Abstract] [Full Text] [Related] Page: [Next] [New Search]